In The Spotlight
Gilead Sciences, Inc. and Kite Pharma, Inc announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash.
Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.
TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced financial and company results for the second quarter of 2017.
TraceLink Inc., the world’s largest track and trace network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced that it has acquired ROC IT Solutions, the leader in intelligent edge data capture for serialized product inventory in the pharmaceutical supply chain.
Valeant Pharmaceuticals International, Inc announced that certain affiliates of the Company have entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. Limited partners of the Fund include industry veterans in other geographic markets, such as China Regenerative Medicine International Limited .
Medicure Inc , a leading Canadian specialty pharmaceutical company, is pleased to announce that it has closed the acquisition of additional interests in Apicore Inc. and Apicore LLC (together "Apicore") from Apicore's founding shareholders as previously announced on July 10, 2017.
Valeant Pharmaceuticals International, Inc. announced that its affiliate has completed the sale of all of the outstanding equity interests in its former subsidiary Dendreon Pharmaceuticals LLC to the Sanpower Group, Co., Ltd. , for $819.9 million in cash.
Imprimis Pharmaceuticals, Inc , an ophthalmology-focused pharmaceutical company, announced it has entered into an agreement to sell its Folcroft, Pennsylvania facility and sinus related assets for $450,000.
Eurofins Scientific , a world leader in biopharmaceutical testing, announces the acquisition of Alphora Research Inc , a full service contract research, development and manufacturing organization (CRDMO) for complex and niche small molecule active pharmaceutical ingredients (APIs), based in Mississauga, Ontario, Canada.
TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, today announced financial and company results for the first quarter of 2017.
A global life science technology firm has surpassed the €20 million milestone for sales of its manufacturing execution system (MES) services.
Imprimis Pharmaceuticals Inc , an ophthalmology-focused pharmaceutical company, announced that it has entered into an licensing agreement for the exclusive worldwide rights to Klarity, an innovative and patented ophthalmic topical solution and gel technology for patients with dry eye disease (DED).
Thermo Fisher Scientific Inc, the world leader in serving science announced that it has acquired Core Informatics, which provides a leading cloud-based platform supporting scientific data management.
Takeda Pharmaceutical Company Limited announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc for $24.00 per share in cash.
Thermo Fisher Scientific Inc, the world leader in serving science completed its previously announced acquisition of Finesse Solutions, Inc., a leader in the development of scalable control automation systems and software for bioproduction.
Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG. As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally.
Quality Packaging Specialists International, LLC (QPSI) has acquired 100% ownership of International Labs, LLC (INL) in an equity exchange transaction.
Mallinckrodt plc , a leading specialty pharmaceutical company, announced today that it has closed the sale of its global Nuclear Imaging business to IBA Molecular (IBAM) for approximately $690 million before tax, including up-front and contingent considerations and the assumption of long-term obligations.
WestRock Company and Multi Packaging Solutions International Limited announced that a definitive agreement has been reached for WestRock to acquire all of the outstanding shares of MPS for $18.00 per share in cash and the assumption of an estimated $873 million in net debt, for a total enterprise value of $2.28 billion.
WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform announced that it has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).
Moberg Pharma AB has now completed the acquisition of DermoPlast® Prestige Brands, Inc. in accordance with the terms announced on December 6. The purchase price was 47.6 million plus inventory value.
OncoGenex Pharmaceuticals, Inc , a publicly held oncology biopharmaceutical company, and Achieve Life Science, Inc , a privately held specialty pharmaceutical company, announced that they have entered into a definitive merger agreement under which OncoGenex will acquire Achieve in an all-stock transaction.
Factor One Source Pharmacy and Fast Access Specialty Therapeutics announced today that they have entered into a definitive agreement under which FOSRx will acquire F.A.S.T. for a combination of cash and stock.
Eli Lilly and Company announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
CSL Limited -At the American Heart Association (AHA) Scientific Sessions in New Orleans, Louisiana, held on 15 November 2016, CSL Behring announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a novel apolipoprotein A-I (apoA-I) infusion therapy.
GlaxoSmithKline plc announced the start of a phase III development programme investigating daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD).
Results from the Phase II SUSTAIN study show that SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) in patients with or without hydroxyurea therapy.
Sun Pharma announced the execution of definitive agreements by its wholly owned subsidiary, for the acquisition of 85.1% of JSC Biosintez, a Russian pharmaceutical company engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region.
Cumberland Pharmaceuticals , a U.S. specialty pharmaceutical company has entered into an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.'s innovative injectable methotrexate product line.
Sorrento Therapeutics, Inc. Virttu, based in Glasgow, Scotland, is a privately-held biopharmaceutical company focused on the development of oncolytic virus therapy for treatment of cancer.
Novartis announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders.
Catalent Inc the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products announced that it has agreed to acquire Accucaps Industries Limited (Accucaps).
Arrow Generiques SAS, the French subsidiary of Aurobindo Pharma Ltd announced the signing of an agreement to acquire select commercial products in France from Teva.
Aegerion Pharmaceuticals Inc and QLT Inc announced the completion of their merger transaction, as a result of which Aegerion is now an indirect wholly-owned subsidiary of QLT. In conjunction with the closing of the merger, QLT changed its name to Novelion Therapeutics Inc.
Aralez Pharmaceuticals Inc a global specialty pharmaceutical company announced that its subsidiary, Aralez Pharmaceuticals Trading DAC (Aralez Ireland), has completed its acquisition of the U.S. rights to Toprol-XL® (metoprolol succinate) and its Authorized Generic (AG) from AstraZeneca.
Lexicon Pharmaceuticals Inc announced that it has obtained exclusive research, development and commercialization rights to LX9211 (BMS-986176), a development candidate for neuropathic pain that was jointly developed by Lexicon and Bristol-Myers Squibb Company as part of their neuroscience drug discovery alliance.
Medivir AB announces that it has entered into an agreement to acquire two clinical stage oncology programs from Tetralogic Pharmaceuticals Corporation , advancing and expanding its clinical pipeline.
Quintiles IMS Holdings has successfully completed its merger of equals transaction between IMS Health Holdings and Quintiles Transnational Holdings.
ICU Medical will acquire all of Pfizer’s global infusion therapy business, Hospira Infusion Systems (HIS), for $1 billion in cash and stock.
GlaxoSmithKline has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings Ltd ("Aspen") at a price of ZAR 300 per share (the "Placing Shares"), raising gross proceeds of approximately ZAR 8,470 million.
PAREXEL International Corporation , a leading global biopharmaceutical services provider announced that the Company has entered into a definitive agreement to acquire ExecuPharm, Inc , a leading, global functional service provider (FSP) serving the biopharmaceutical industry.
Pfizer Inc announced the successful completion of its acquisition of Medivation, Inc . As of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately 69.1% of the shares outstanding and have been accepted for payment under the terms of the tender offer for $81.50 per share in cash, without interest, subject to any required withholding of taxes.
In announcing the result, Amcor’s Managing Director & CEO, Mr Ron Delia said: “, Amcor reported a strong full year result with growth in earnings, returns and cash flow delivered in a challenging macroeconomic environment.
Sonoco ThermoSafe has acquired the PharmaPort 360™ assets, licenses, trademarks and manufacturing rights from AAR, to enter the active temperature-controlled cargo containers market.
The global rigid film producer Klöckner Pentaplast will acquire Farmamak Review from Venture Capital Investment Trust Inc. (Review Initiative). Farmamak will operat on as a subsidiary within the Klöckner Pentaplast Group.
Ball Corporation published its fifth biennial sustainability report, which details the company's progress toward its updated priorities – product stewardship, operational excellence, talent management and community ambassadors – and sets a clear path for the future with 10 new ambitious goals to be achieved by 2020.
Pfizer Inc announced that it has entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infectives business, primarily outside the United States.
Momenta Pharmaceuticals, Inc reported its financial results for the second quarter ended June 30, 2016.For the second quarter of 2016, the Company reported total revenues of $26.4 million, including $20.7 million in product revenues from Sandoz's sale of Glatopa® (glatiramer acetate injection).
Boehringer Ingelheim reported currency-adjusted growth in all its core businesses in the first half of 2016. At the same time, the research-driven pharmaceutical company achieved key strategic milestones by signing contracts to exchange businesses with Sanofi and completing the internal restructuring of its human pharmaceuticals business. For the current year, Boehringer Ingelheim is still expecting a slight year-on-year increase in currency-adjusted net sales.
• Half-year net sales of approximately 7.3 billion euro
• Currency-adjusted net sales growth of 2%
• Key strategic milestones achieved
In the first half of 2016, Boehringer Ingelheim generated total net sales of approximately 7.3 billion euros, which after currency adjustment represents an increase of 2% compared with the same period last year (-1% in euro terms). Excluding the US generics business Roxane, which was sold in February, currency-adjusted growth in the first six months of the financial year amounted to as much as 5% (+1% in euro terms).
Product launches drive growth
Prescription medicines, Boehringer Ingelheim’s biggest business, achieved net sales of 5.45 billion euros in the first half of the year. This represents a currency-adjusted increase of 4% (+1% in euro terms). As in prior years, the respiratory medicine SPIRIVA® for the treatment of COPD and asthma was the top-selling medicine, despite its patent expiring in some markets. Boehringer Ingelheim generated net sales of some 1.46 billion euros with the product, which represented a currency-adjusted decline of 16%, as expected (-17% in euro terms).
This effect was, however, more than offset by the very gratifying net sales performance of new medicines. The diabetes portfolio was an important growth driver in the first half of the year, with an increase of 55% after currency adjustment to 760 million euros (+53% in euro terms). A positive development from a medical perspective was new data on JARDIANCE® (empagliflozin) in the treatment of type 2 diabetes: it demonstrated that, when taken in addition to the standard treatment, the medicine reduced the risk of a reoccurrence or a deterioration of renal disease in patients with type 2 diabetes and existing cardiovascular disease by 39% compared to the placebo. Empagliflozin is thus the only SGLT2 inhibitor that could slow the progression of renal disease in people with type 2 diabetes and cardiovascular disease in a cardiovascular outcome study.
Strong growth was also reported for OFEV® for treating idiopathic pulmonary fibrosis (IPF) – net sales were up by 166% to 250 million euros (+166% in euro terms). With its anticoagulant PRADAXA® Boehringer Ingelheim generated net sales of 650 million euros corresponding to a currency-adjusted increase of 6% (+4% in euro terms).
Net sales of over-the-counter medicines rose by 5% on a currency-adjusted basis in the reporting period to 750 million euros (-4% in euro terms). That amounts to over 10% of total net sales. International core brands are DULCOLAX®, BUSCOPAN®, PHARMATON®, MUCOSOLVAN® and BISOLVON®.
In the animal health business, Boehringer Ingelheim achieved currency-adjusted growth of 6% in the first half of 2016, amounting to 688 million euros (+4% in euro terms). This corresponds to 9.5% of total net sales.
The biopharmaceuticals business, in which Boehringer Ingelheim is exclusively involved in contract manufacturing for third parties, grew slightly by 1% to 216 million euros. In the coming years,
Boehringer Ingelheim is planning to invest more than 0.5 billion euros in biopharmaceutical production at its site in Vienna, Austria.
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.For more information please visit www.boehringer-ingelwww.boehringer-ingelheim.comheim.com
Group sales increase by 2.3 percent (Fx & portfolio adj.) to EUR 11,833 million / Pharmaceuticals continues strong growth trend / Consumer Health increases sales / Crop Science business holds steady in a continuingly difficult market environment / EBITDA before special items up 5.7 percent to EUR 3,054 million / Net income improves by 18.6 percent to EUR 1,380 million / Core earnings per share increase by 4.0 percent to EUR 2.07 / Group forecast raised.
Gilead Sciences, Inc announced that its second quarter 2016 financial results will be released on Monday, July 25, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2016 and provide a general business update.
GSK delivers further progress against strategy with strong Q2 performance
Group sales £6.5 billion, +4% CER, with growth across all three businesses
Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2016 of $0.80 per share on the company’s common stock. The dividend is payable on September 6, 2016 to shareholders of record at the close of business on August 23, 2016. The ex-dividend date is August 19, 2016.
Johnson & Johnson announced that Johnson & Johnson Consumer Inc. has successfully completed the acquisition of Vogue International LLC, a privately-held company focused on the marketing, development and distribution of salon-influenced and nature inspired hair care and other personal care products, for $3.3 billion in cash.
Merck known as MSD outside the United States and Canada announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the fourth quarter of 2016. Payment will be made on Oct. 7, 2016 to shareholders of record at the close of business on Sept. 15, 2016.
Pfizer Inc announced that it has acquired Bamboo Therapeutics, Inc., a privately held biotechnology company based in Chapel Hill, N.C., focused on developing gene therapies for the potential treatment of patients with certain rare diseases related to neuromuscular conditions and those affecting the central nervous system.
Alexion Pharmaceuticals, Inc. announced that the Company will report its financial results for the second quarter ended June 30, 2016 on Thursday, July 28, 2016 before the US financial markets open.
Bristol-Myers Squibb Company and Cormorant Pharmaceuticals announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases.
- Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth
- Cosentyx (USD 260 million) grew strongly driven by its three approved indications
Pfizer Inc announced that it has completed its acquisition of Anacor Pharmaceuticals, Inc. Under the terms of the transaction, each outstanding share of Anacor common stock has been converted into the right to receive $99.25 net in cash (without interest but subject to required withholding of taxes).
Bristol-Myers Squibb Company will announce results for the second quarter of 2016 on Thursday, July 28, 2016. During a conference call at 10:30 a.m. EDT on July 28, company executives will review financial information and will address inquiries from investors and analysts.
Merck known as MSD outside the United States and Canada, announced that Dr. Roger M. Perlmutter, president, Merck Research Laboratories, will present an overview of the company’s oncology program at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 6, 2016 at 5:45 p.m. CDT (6:45 p.m. EDT).
Peregrine Pharmaceuticals, Inc announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
Baxalta Incorporated , Velocity Pharmaceutical Development, LLC and Astellas Pharma Inc announced that Thunderbolt, Inc., a company established by Vitesse Biologics, acquired all rights to the Astellas BAFF/APRIL dual antagonist program through an asset purchase agreement. The BAFF/APRIL dual antagonists will be developed for B cell disorders including systemic lupus erythematosus.
Merck announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the third quarter of 2016. Payment will be made on July 8, 2016 to shareholders of record at the close of business on June 15, 2016.
- Healthcare and Life Science drive Group organic sales growth (+4.7%)
- Sigma-Aldrich acquisition fuels sales (+20.5%) and EBITDA pre exceptionals (+27.0%)
- Integration of Sigma-Aldrich proceeding according to plan
- Net financial debt lowered by around € 600 million
- Merck confirms and specifies outlook for 2016
Sanofi Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Medivation
- Strong fit with Pfizer’s Inflammation and Immunology portfolio
- Expected to enhance near-term revenue growth for the innovative business
- Anacor’s flagship asset, crisaborole, has a New Drug Application under review by the U.S. Food and Drug Administration (FDA), is a differentiated non-steroidal topical PDE4 inhibitor with compelling clinical data, and if approved, has the potential to be an important first-line treatment option for patients with atopic dermatitis
- Group sales rise by 2 percent – adjusted by +4 percent
- Adjusted EBITDA declines slightly by 1 percent
- Adjusted net income increases by 6 percent
- Sales increase in Branded Products by +3 percent – adjusted +4 percent
- Very positive development of the German Generics segment +8 percent – solid sales development in Central Europe +2 percent and Asia/Pacific & MENA +6 percent, CIS/Eastern Europe -15 percent due to currency effects – adjusted slightly above the level of the previous year
- Outlook for 2016 confirmed
Revenue reached DKK 3,770 million in the first quarter of 2016 representing an increase of 6% both reported and in local currencies compared to the same period last year
Bayer and BioNTech AG, a leading immunotherapy company headquartered in Mainz, Germany have entered into an agreement to develop novel, first-in-class mRNA vaccines and therapeutics specifically for Animal Health applications.
Acquisition of Nitinol Implant Company Strengthens Johnson & Johnson Medical Devices Position in Elective Extremity Surgery, the Fastest Growing Segment in Orthopaedics.
AstraZeneca announced that it has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company Limited . The agreement, announced in December 2015, includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease. AstraZeneca has marketed Daliresp in the US since the acquisition of the rights from Actavis in the first quarter of 2015.
Sales increased by 9% in local currencies and by 8% in Danish kroner to DKK 27.2 billion.
- Sales of Victoza® increased by 15% (16% in Danish kroner).
- Sales of Levemir® increased by 9% (8% in Danish kroner).
- Sales of Tresiba® increased by 117% (113% in Danish kroner).
- Sales in USA increased by 12% (14% in Danish kroner).
- Sales in International Operations increased by 15% (3% in Danish kroner).
- Combination will create a premier medical device leader and strengthen abbott's long-term growth potential
- Acquisition will enhance abbott's global scale and capabilities and will further diversify its portfolio of best-in-class products and revenue sources
- Combined portfolio will include top positions in high-growth markets and an industry-leading pipeline
- Transaction expected to be accretive to abbott's adjusted earnings per share(1) in the first full year after closing and increasing thereafter
Aspen Technology, Inc ,a leading provider of software and services to the process industries, today announced financial results for its third quarter of fiscal year 2016, ended March 31, 2016.
Bayer interim report for the first quarter shows a successful start of 2016
Substantial sales growth at Pharmaceuticals / Earnings expand in all segments / Group sales increase to EUR 11,941 million (plus 0.5 percent / Fx & portfolio adj. plus 3.2 percent) / EBITDA before special items advances by 15.7 percent to EUR 3,404 million / EBIT up 20.1 percent to EUR 2,335 million / Net income grows by 13.3 percent to EUR 1,511 million / Core earnings per share up 13.9 percent to EUR 2.37 / Outlook for 2016 confirmed
Positive Sales Mix and Disciplined Expense Management Contribute to Strong First Quarter Performance; Adjusted Earnings Per Share were $0.36; First-quarter GAAP Earnings Per Share were $6.13
Johnson & Johnson announced sales of $17.5 billion for the first quarter of 2016, an increase of 0.6% as compared to the first quarter of 2015. Operational sales results increased 3.9% and the negative impact of currency was 3.3%. Domestic sales increased 7.2%. International sales decreased 6.0%, reflecting operational growth of 0.6% and a negative currency impact of 6.6%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 6.9%, domestic sales increased 9.8% and international sales increased 3.8%. The currency devaluation in Venezuela negatively impacted worldwide operational sales growth by 60 basis points, and international sales growth by 120 basis points.
- Net sales rise to 14.8 billion euros (currency-adjusted: +4.1 per cent; +11.1 per cent in euro terms)
- Operating income improves markedly to 2.3 billion euros
- Key strategic course set for future sustainable business development
Teva Pharmaceutical Industries Ltd announced that it will release its first quarter 2016 financial results on Monday, May 9, 2016 at 7:00 a.m. ET.
Eli Lilly and Company announced it will host a meeting for the investment community, including institutional investors, sell-side analysts, ratings agency representatives, and financial and business media.
CTI BioPharma Corp. announced that it has entered into an agreement with institutional investors to purchase 10 million shares of the Company's common stock in a registered direct offering conducted without an underwriter or placement agent for gross proceeds to the Company of approximately $15.7 million at a purchase price per share of $1.57 (the "Offering"), equal to the consolidated closing bid price on The NASDAQ Global MarketSM on September 23, 2015. The net proceeds from the Offering, after deducting estimated offering expenses, will be approximately $15.1 million.
Seattle Genetics and Bristol-Myers Squibb (BMS) have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Adcetris and Opdivo in two planned Phase I/II clinical trials.
Irish drugmaker Shire has signed a merger agreement to acquire US-based NPS Pharmaceuticals for $5.2bn.
US-based drug maker Pfizer has completed the acquisition of marketed vaccines portfolio from Baxter International for $635m.
US-based Johnson & Johnson (J&J) has completed the acquisition of a privately held clinical stage biopharmaceutical company, AliosBioPharma, for $1.75bn in cash.
Aegerion Pharmaceuticals has signed an agreement to acquire an orphan product Myalept (metreleptin for injection) from AstraZeneca.
Sales of $19.5 Billion increased 9.1% Versus 2013 Second Quarter; Second-Quarter EPS was $1.51 Excluding Special Items, 2014 Second-Quarter EPS of $1.66 increased 12.2%*
Pivotal Therapeutics Inc. , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2014. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
China Nepstar Chain Drugstore Ltd., a leading retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the first quarter ended March 31, 2014.
Adocia announces today its annual financial results for 2013. The financial statements were approved by the board of directors on March 21, 2014 and will be submitted to the shareholders for approval during the next general meeting on June 24, 2014.
Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic molecules, in particular proteins and oncologic drugs, announces today its revenue for the last quarter 2013 and full year end.
Bristol-Myers Squibb Company (NYSE:BMY) has reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model.